Cadila Healthcare gets DCGI nod to conduct phase III trials for two-dose COVID vaccine

06 Oct 2021 Evaluate

Cadila Healthcare has received permission from the Drug Controller General of India (DCGI) for conducting phase III trials for its two-dose COVID-19 vaccine ZyCoV-D. The company has already received the emergency use authorization (EUA) from the DCGI for ZyCoV-D to be administered in three doses on August 20, 2021.

Cadila Healthcare is an India-based pharmaceutical company. The company's subsidiaries include Zydus Wellness, Liva Pharmaceuticals, Biochem Pharmaceutical Industries, Zydus Technologies, German Remedies, Dialforhealth India, Dialforhealth Unity and Dialforhealth Greencross, among others.

Zydus Lifesciences Share Price

867.80 -16.20 (-1.83%)
16-Jan-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1669.20
Dr. Reddys Lab 1175.55
Cipla 1397.95
Zydus Lifesciences 867.80
Lupin 2176.25
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×